Monitoring pulmonary complications in lnog-term childhood cancer survivors: Guidelines for the primary care physician

Cleveland Clinic Journal of Medicine

Volumn 75, Issue 7, 2008, Pages 531-539

  Liles, Allen ^a,b   Blatt, Julie ^b,c   Morris, David ^a,b   Wardrop III, Richard ^b,d   Sharma, Anjali ^b,e   Sznewajs, Aimee ^b,e   Goldsby, Robert ^b,e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

GENERAL PRACTITIONER; HUMAN; LUNG DISEASE; NEOPLASM; RADIOTHERAPY; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION; SURVIVOR; TIME;

ANTINEOPLASTIC AGENTS; HUMANS; LUNG DISEASES; NEOPLASMS; PHYSICIANS, FAMILY; RADIOTHERAPY; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVORS; TIME FACTORS;

EID: 51249118364     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.75.7.531     Document Type: Review

References (38)

1. Hewitt M, Weiner S, Simone J. The epidemiology of childhood cancer. Washington DC: The National Academies Press, 2003:20-36.
2. Ries L, Eisner M, Kosary C. et al. SEER cancer statistics review, 1975-2001. Bethesda, MD: National Cancer Institute, 2004.
3. Landier W, Ohatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and nursing discipline. J Clin Oncol 2004; 22:4979-4990.
4. Mertens AC, Yasui Y, Liu Y, et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer 2002; 95:2431-2441.
5. Bhatia S, Blatt J, Meadows A. Late effects of childhood cancer and its treatment. In: Pizzo P, Poplack D. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams & Wilkins, 2006.
6. Anscher MS, Chen L. Rabbani Z, et al. Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Int J Radiat Oncol Biol Phys 2005; 62:255-259.
7. Bhatt N, Baran CP, Allen J. et al. Promising pharmacologic innovations in treating pulmonary fibrosis. Curr Opin Pharmacol 2006; 6:284-292.
8. Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 2001:13:242-248.
9. Horning SJ, Adhikari A, Rizk N, et al. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol 1994; 12:297-305.
10. Villani F, Viviani S, Bonfante V, et al. Late pulmonary effects in favorable stage I and IIA Hodgkin's disease treated with radiotherapy aone. Am J Clin Oncol 2000; 23:18-21.
11. Miller RW, Fusner JE, Fink RJ, et al. Pulmonary function abnormalities in long-term survivors of childhood cancer. Med Pediatr Oncol 1986; 14:202-207.
12. Weiner DJ, Maity A, Carlson CA. et al. Pulmonary function abnormalities in children treated with whole lung irradiation. Pediatr Blood Cancer 2006; 46:222-227.
13. Wohl ME, Griscom NT, Traggis DG, et al. Effects of therapeutic irradication delivered in early childhood upon subsequent lung function. Pediatrics 1975; 55:507-516.
14. Hudson MM, Greenwald C, Thompson E, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 1993; 11:100-108.
15. Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol 2004; 22:4541-4550.
16. Quigley PM, Yeager AM, Loughlin GM. The effects of bone marrow transplantation on pulmonary function in children. Pediatr Pulmonol 1994, 18:361-367.
17. Farad M, Barra S, Cohen A, et al. Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. Int J Radiat Oncol Biol Phys 2005; 63:1568-1575.
18. Eigen H, Wyszomierski D. Bleomycin lung injury in children. Pathophysiology and guidelines for management. Am J Pediatr Hematol Oncol 1985; 7:71-78.
19. Goldiner PL, Schweizer O. The hazards of anesthesia and surgery in bleomycin-treated patients. Semin Oncol 1979; 6:121-124.
20. Zaniboni A, Prabhu S, Audisio RA. Chemotherapy and anaesthetic drugs: too little is known. Lancet Oncol 2005; 6:176-181.
21. Aranin PA, Mahaley MS Jr, Rudnick SA. et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med 1980; 303:183-188.
22. O'Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990; 323:378-382.
23. Alvarado CS, Boat TF, Newman AJ. Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide. J Pediatr 1978; 92:443-446.
24. Codling BW, Chakera TM. Pulmonary fibrosis following therapy with melphalan for multiple myeloma. J Clin Pathol 1972; 25:668-673.
25. Bruno B, Souillet G, Bertrand Y, et al. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre. Bone Marrow Transplant 2004, 34:143-147.
26. Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005; 4:723-730.
27. Cottin V, Tebob J, Massoennet B, et al. Pulmonary function in patients receiving long-term methotrexate. Chest 1996;109:933-938.
28. Gutin PH, Green MR, Bleyer WA, et al. Methotrexate pneumonitis induced by intrathecal methotrexate therapy: a case report with pharmacokinetic data. Cancer 1976; 38:1529-1534.
29. Konits PH, Aisner J, Sutherland JC, et al. Possible pulmonary toxicity secondary to vinblastine. Cancer 1982; 50:2771-2774.
30. Cerveri I, Zola MC, Fulgoni Pe et al. Late pulmonary sequelae after childhood bone marrow transplantation. Thorax 1999; 54:131-135.
31. Cerveri I, Fulgoni P, Giorgiani G. et al. Lung function abnormalities after bone marrow transplantation in children: has the trend recently changed? Chest 2001; 120:1900-1906.
32. Neve V, Foot AB, Michon J, et al. Longitudinal clinical and functional pulmonary follow-up after megatherapy, fractionated total body irradiation, and autologous bone marrow transplantation for metastatic neuroblastoma. Med Pediatr Oncol 1999; 32:178-176.
33. Nenadov Beck M, Meresse V, Hartmann O. et al. Long-term pulmonary sequelae after autologous bone marrow transplantation in children without total body irradiation. Bone Marrow Transplant 1995; 16:771-775.
34. Huls G. ten Bokkell Hulnink D. Bleomycin and scuba diving: to dive or not to dive? Neth J Med 2003, 61:50-53.
35. Kreisel D, Krupnick AS, Huddleston CB. Outcomes and late complications after pulmonary resections in the pediatric population. Semin Thorac Cardiovasc Surg 2004; 16:215-219.
36. Lezama-del Valle Valle P, Blakely ML, Lobe TE. Physiologic consequences of pneumonectomy. Long-term consequences of pneumonectomy done in children. Chest Surg Clin North Am 1999; 9:485-495.
37. Tobias A Bozeman PM, Mackert PW, et al. Postoperative outcome following thoracotomy in the pediatric oncology patient with diminished pulmonary function. J Surg Oncol 1993; 52:105-109.
38. Drugs for Tobacco Dependence. Treatment Guidelines from the Medical Letter. June, 2003:1(10):65-68.